Full-Time
IT G&A Business Analyst
Updated on 8/20/2026
Rhythm Pharmaceuticals
201-500 employees
Commercializes MC4R-targeted therapies for rare obesity
Compensation Overview
$110k - $165k/yr
Boston, MA, USA
Hybrid
Hybrid work requires attendance at the Boston office based on department and business needs.
Bachelor's
 IT & Security (1) |
|---|
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree in computer science or a related field is required.
- Three to five years of experience working with a combination of G&A business applications such as Ironclad, Coupa, MediSpend, and ADP or similar platforms is required.
- Experience supporting applications within the pharmaceutical or biotechnology industry is required.
- Proficiency with Microsoft Office Suite, including Excel, Word, and PowerPoint, is required.
- The role requires the ability to manage work requests across multiple business areas independently and influence outcomes in a hands-on capacity.
- Strong analytical skills are required, including the ability to interpret customer business needs and translate them into application and operational requirements.
- Excellent written and verbal communication and interpersonal skills are required.
- The role supports IT initiatives for General and Administrative functions, focusing on Legal, Human Resources, and Procurement activities.
- The role supports the implementation and maintenance of Ironclad Contracts Management, Coupa Procure to Pay, Porzio Transparency Spend, and related systems in a global environment.
- The role develops business and technical requirements through interviews, workshops, document analysis, business process descriptions, use cases, scenarios, business analysis, and task and workflow analysis.
- The role participates in managing external partners supporting business and technical requirements.
- The role coordinates issue resolution with internal and external support partners.
- The role supports healthcare professional engagement and global compliance activities.
- The role supports change management and governance activities by partnering with the business to ensure new items are tested and implemented according to the systems life cycle.
- The role leads test-script creation, user testing, and user documentation for systems.
- The role ensures that appropriate IT processes, procedures, and standards are followed.
- The role contributes to developing IT processes, tools, and standards.
- The role develops effective relationships among the business, partners, and the Information Technology organization.
- The role assists with successful implementation and support of company systems.
- The role communicates with cross-functional leads, team members, and senior leadership about status, risks, and related topics.
- The role contributes to technology strategy through change-management activities.
- The role works on other processes, functions, technologies, and projects based on company priorities.
- Familiarity with Smartsheet or Microsoft Project is preferred.
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.
Company Size
201-500
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2008
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 IMCIVREE revenue reached $71.3 million, up 19% sequentially.
- August 2026 RM-718 delivered 11.6% BMI reduction at week 16 in HO patients.
- August 2026 Manher Joshi joined as CMO, strengthening late-stage development execution.
What critics are saying
- March 2026 EMANATE missed four primary endpoints, weakening expansion beyond current labels.
- IMCIVREE depends on rare-disease diagnosis, payer access, and narrow prescriber adoption.
- Setmelanotide-class adverse events, including nausea and injection reactions, threaten chronic-use persistence.
What makes Rhythm Pharmaceuticals unique
- March 2026 FDA approved IMCIVREE first for acquired hypothalamic obesity.
- Rhythm owns MC4R biology, spanning setmelanotide, bivamelagon, and RM-718 programs.
- BBS and genetic-obesity diagnostics create a rare, specialist-driven commercial moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 3%Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.
Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.
Rhythm Pharmaceuticals reported preliminary results showing its experimental weekly injectable drug RM-718 helped reduce body weight in patients with acquired hypothalamic obesity, a rare condition caused by brain damage from tumour surgery or treatment. The Boston-based company's shares rose 5% in premarket trading. Among 11 enrolled patients, seven who completed 16 weeks of treatment saw their body mass index fall by an average of 11.6%. The drug works by activating the MC4R brain receptor, which controls hunger and metabolism. Two patients discontinued treatment due to side effects including nausea and injection site problems. Rhythm also sells setmelanotide for the same condition under the brand name Imcivree. Separately, the company reported second-quarter revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE, marking a 19% sequential increase from the first quarter. The company received over 400 patient start forms for IMCIVREE's acquired hypothalamic obesity indication from approximately 300 prescribers as of 30 June 2026, following FDA approval in March. US revenue reached $51.0 million, representing 72% of product revenue and a 38% sequential increase, driven primarily by acquired hypothalamic obesity demand. The company reported preliminary Phase 2 data showing weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in acquired hypothalamic obesity patients after 16 weeks. Cash, cash equivalents, and short-term investments totalled approximately $330.9 million as of 30 June 2026. The company posted a net loss of $50.4 million for the quarter.
Rhythm Pharmaceuticals has published an updated diagnostic algorithm for Bardet-Biedl syndrome in the American Journal of Medical Genetics, designed to help clinicians achieve faster diagnoses using modern genetic testing. The evidence-based framework simplifies recognition of the complex, multi-organ rare disease across age groups and specialties. The new algorithm could expand identification of eligible patients for Rhythm's IMCIVREE treatment and strengthen relationships with the Bardet-Biedl syndrome community and physicians. This follows Rhythm's recent expanded indication for IMCIVREE in acquired hypothalamic obesity in the US and Europe. Whilst the algorithm may broaden patient identification, investors remain focused on Rhythm's commercial execution, persistent operating losses and reliance on setmelanotide. The company's investment case depends on converting rare genetic obesity awareness into sustainable treatment demand.